[1]Welslau M , Hartkopf A D , Volkmar Müller, et al. Update Breast Cancer 2019 Part 5 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer[J]. Geburtshilfe und Frauenheilkunde, 2019, 79(10):1090-1099.
[2]Tarantino P, Morganti S, Uliano J, et al. Margetuximab for the treatment of HER2-Positive Metastatic Breast Cancer[J]. Expert Opinion on Biological Therapy, 2020.
[3]Kreutzfeldt J, Rozeboom B, Dey N, et al. The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies[J]. American Journal of Cancer Research, 2020, 10(4): 1045.
[4]Dobson R. Trastuzumab halves risk of recurrence of breast cancer in some women[J]. BMJ, 2005, 331(7523): 986.
[5]Bang Y J, Giaccone G, Im S A, et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors[J]. Annals of Oncology, 2017, 28(4): 855-861.
[6]NCCN Guidelines Version 5. 2020-Breast Cancer.
[7]https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[8] http://www.chinadrugtrials.org.cn